<DOC>
	<DOCNO>NCT00682981</DOCNO>
	<brief_summary>The Phase I portion protocol determine best phase II dose schedule obatoclax carboplatin etoposide patient extensive-stage small cell lung cancer . The Phase II portion evaluate response rate regimen .</brief_summary>
	<brief_title>A Phase I/II Study Carboplatin Etoposide With Without Obatoclax Extensive-stage Small Cell Lung Cancer ( ES-SCLC )</brief_title>
	<detailed_description>In Phase I portion , 3 hour 24 hour infusion obatoclax carboplatin etoposide every 3 week evaluate different dos . In Phase II portion , 3 hour infusion obatoclax without carboplatin etoposide every three week evaluate response rate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Phase I : Pathological cytological confirmation SCLC ESSCLC Measurable disease use Response Evaluation Criteria Solid Tumors ( RECIST ) least one lesion ≥2.0 cm use conventional technique ≥1.0 cm spiral compute tomography ( CT ) scan single dimension No previous chemotherapy Age ≥18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤1 Normal organ function define : absolute neutrophil count ( ANC ) 1500/mm3 , platelet ≥100,000/mm3 , total bilirubin ≤ upper limit normal ( ULN ) total bilirubin ≤ 3.0 liver metastasis present , alanine aminotransferase ( serum glutamic pyruvic transaminase ) ( ALT [ SGPT ] ) 2.5 ´ ULN ALT/SGPT ≤ 5 ´ ULN liver metastasis present , creatinine within normal institutional limit calculate creatinine clearance ≥50 mL/min/1.73 m2 patient creatinine level institutional normal Negative serum urine pregnancy test result prior study entry . In addition , woman childbearing potential men partner childbearing potential must agree use acceptable form birth control ( result le 1 % pregnancy/year use correctly : implant , injectables , combine oral contraceptive , IUDs , vasectomy male partner , sexual abstinence ) Ability understand willingness sign write informed consent form Phase II : Pathological cytological confirmation SCLC ESSCLC Measurable disease use RECIST criterion least one lesion 2.0 cm use conventional technique ≥1.0 cm spiral CT scan single dimension No previous chemotherapy Age ≥18 year ECOG Performance Status ≤2 ; Normal organ function define : ANC ≥1500/mm3 , platelet ≥100,000/mm3 , total bilirubin ≤ULN total bilirubin ≤ 3.0 liver metastasis present , ALT ( SGPT ) ≤2.5 ´ ULN ALT/SGPT ≤ 5 ´ ULN liver metastasis present , creatinine within normal institutional limit calculate creatinine clearance ≥50 mL/min/1.73 m2 patient creatinine level institutional normal Negative serum urine pregnancy test result prior study entry . In addition , woman childbearing potential men partner childbearing potential must agree use acceptable form birth control ( result le 1 % pregnancy/year use correctly : implant , injectables , combine oral contraceptive , IUDs , vasectomy male partner , sexual abstinence ) Ability understand willingness sign write informed consent form Phase I II : Other investigational commercial agent therapy administer intent treat patient 's malignancy History allergic reaction attribute component obatoclax formulation ( Polysorbate 20 PEG 300 ) History seizure disorder unrelated SCLC brain metastasis , presence symptomatic brain metastasis Uncontrolled , intercurrent illness include , limited , symptomatic neurological illness ; active , uncontrolled systemic infection consider opportunistic , lifethreatening , clinically significant time treatment ; symptomatic congestive heart failure ; unstable angina pectoris ; clinically significant cardiac arrhythmia ; significant pulmonary disease hypoxia ; psychiatric illness/social situation would limit compliance study requirement Pregnant woman woman breast feeding ; human immunodeficiency virus ( HIV ) positive patient receive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ES-SCLC</keyword>
	<keyword>Obatoclax</keyword>
</DOC>